Summary

The in vitro toxicology testing market is projected to reach USD 20.97 billion by 2031, growing from an estimated USD 12.69 billion in 2026, at a CAGR of 10.6% during the forecast period. Growth is being driven by increasing use of cell-based assays, 3D culture models, organoids, organ-on-chip systems, high-content screening, automation, and AI-enabled predictive toxicology for early-stage compound screening and safety profiling. The market is further supported by rising pharmaceutical and biotechnology R&D spending, demand for faster and more human-relevant toxicity prediction, outsourcing to CROs, and regulatory momentum to reduce animal testing while improving preclinical decision-making. “The products segment accounted for a larger share than the services segment in 2025.” By offering, the products segment accounted for the largest share in the global in vitro toxicology testing market. The products segment led the market because in vitro toxicology workflows depend heavily on recurring product consumption, including assay kits, reagents, cell culture media, sera, buffers, microplates, detection substrates, reference standards, and validated cell models. Unlike services, these products are repeatedly required across every cytotoxicity, genotoxicity, organ toxicity, dermal, ocular, and mechanistic toxicity study. “North America dominated the in vitro toxicology testing market in 2025.” North America dominated the in vitro toxicology testing market in 2025, primarily due to the strong presence of pharmaceutical and biotechnology companies, advanced CRO infrastructure, well-funded academic research centers, and early adoption of non-animal safety testing technologies across the US and Canada. The region has high demand for cytotoxicity, genotoxicity, hepatotoxicity, cardiotoxicity, and mechanistic toxicity testing during drug discovery, preclinical development, cosmetics safety assessment, chemical evaluation, and medical device biocompatibility testing. The US also has a mature ecosystem of assay kit suppliers, cell model providers, organ-on-chip companies, high-content screening platforms, and predictive toxicology software developers, supporting broad commercialization of in vitro toxicology products and services. Regulatory modernization initiatives encouraging alternative methods to animal testing further support adoption. The primary interviews conducted for this report can be categorized as follows: ・ By Respondent: Supply Side - 70%; Demand Side 30% ・ By Designation: Managers - 45%; CXO & Directors - 30%; and Executives - 25% ・ By Region: North America - 40%; Europe - 25%; Asia Pacific - 20%; Latin America - 10%; and Middle East & Africa - 5% List of Companies Profiled in the Report: ・ Thermo Fisher Scientific Inc. (US) ・ Merck KGaA (Germany) ・ Eurofins Scientific (Luxembourg) ・ Laboratory Corporation of America Holdings (US) ・ Charles River Laboratories (US) ・ SGS SA (Switzerland) ・ Bio-Rad Laboratories, Inc. (US) ・ Evotec SE (Germany) ・ Promega Corporation (US) ・ Catalent, Inc. (US) ・ Agilent Technologies, Inc. (US) ・ Intertek Group plc (UK) ・ Revvity (US) ・ Inotiv (US) ・ BioIVT (US) ・ Lonza (Switzerland) ・ Creative Biolabs (US) ・ Shanghai Medicilon Inc. (China) ・ Creative Bioarray (US) ・ Aragen Life Sciences Ltd. (India) ・ Enzo Biochem Inc. (US) ・ Microbac Laboratories, Inc. (US) ・ Vimta Labs Ltd. (India) ・ Pacific BioLabs Inc. (US) ・ MB Research Laboratories (US) Research Coverage: This research report categorizes the in vitro toxicology testing market by offering {Products [Reagents & Consumables (Cell Lines & Primary Cells, Culture Reagents, Media & Consumables, 3D Models and Tissue Systems, Other Reagents & Consumables), Assay Kits (Cytotoxicity Assay, Genotoxicity Assay, Organ-Specific Toxicity Assay, Other Assays), Equipment (Detection, Imaging & Analytical Systems (Imaging Systems, Detection Instruments, Other Instruments), Liquid Handling & Automation Systems, Other Equipment), Software & Informatics, and Services; Product - By Toxicity End Point (Organ Toxicity Testing, Cytotoxicity Testing, Genotoxicity Testing, Dermal Toxicity and Skin Irritation, Corrosion and Sensitization, Oxidative Stress and Mechanistic Toxicity, Other Toxicity Endpoints and Tests); Product - By Technology (Cell Culture Technologies, High-Throughput and High-Content Technologies, Omics Technologies, Organotypic and Microphysiological Based Technologies, Other Technologies); Product - By Method (Cell-Based Toxicity Testing Method, Biochemical Toxicity Testing Method, In Silico/Computational Toxicity Testing Method, Ex Vivo Models-Based Toxicity Testing Method, Molecular & Omics-Based Toxicology Method, Other Methods); Product - By End User (Pharmaceuticals & Biotechnology Companies, Consumer Care Companies, Food & Beverages Companies, Cros, Academic And Research Institutes, Other End Users); Service- By Type (Toxicology Testing Service, Biological Model And Assay Development Services, Imaging And Analytical Toxicology Services, Data Analysis, Bioinformatics, And Predictive Toxicology); Service - By Method (Cell-Based Toxicity Testing Method, Biochemical Toxicity Testing Method, In Silico/Computational Toxicity Testing Method, Ex Vivo Models-Based Toxicity Testing Method, Molecular & Omics-Based Toxicology Method, Other Methods); Service - By End User (Pharmaceuticals & Biotechnology Companies, Consumer Care Companies, Food & Beverages Companies, Academic And Research Institutes, Other End Users). The report’s scope encompasses detailed information regarding major influencing factors such as drivers, trends, challenges, and opportunities shaping the growth of the in vitro toxicology testing market. A comprehensive analysis of key industry players has been conducted to offer insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. The report also covers recent developments, including new product launches, mergers, and acquisitions, in the in vitro toxicology testing market. Key Benefits of Buying the Report: The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall in vitro toxicology testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: ・ Analysis of key drivers (Growing industry shift toward non-animal toxicology testing methods, increasing technological advancements), restraints (Limited in vivo-to-in vitro correlation for complex endpoints), opportunities (AI/ML-powered predictive toxicology, increasing focus on drug discovery using in vitro methods, cannabis, e-cigarette, and novel product safety testing), and challenges (Ethical and regulatory challenges in AI-driven toxicology), influencing the growth of the market ・ Product/Service Development/Innovation: Detailed insights on newly launched products/services of the in vitro toxicology testing market ・ Market Development: Comprehensive information about lucrative markets across varied regions ・ Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the in vitro toxicology testing market ・ Competitive Assessment: Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), SGS SA (Switzerland), Bio-Rad Laboratories, Inc. (US), Evotec SE (Germany), Promega Corporation (US), Catalent, Inc. (US), Agilent Technologies, Inc. (US), Intertek Group plc (UK), Revvity (US), Inotiv (US), BioIVT (US), Lonza (Switzerland), Creative Biolabs (US), Shanghai Medicilon Inc. (China), Creative Bioarray (US), Aragen Life Sciences Ltd. (India), Enzo Biochem Inc. (US), Microbac Laboratories, Inc. (US), Vimta Labs Ltd. (India), Pacific BioLabs Inc. (US), and MB Research Laboratories (US), among others, in the market

ページTOPに戻る

Table of Contents

1 INTRODUCTION 60
1.1 STUDY OBJECTIVES 60
1.2 MARKET DEFINITION 60
1.3 MARKET SCOPE 61
1.3.1 MARKETS COVERED 61
1.3.2 INCLUSIONS & EXCLUSIONS 62
1.3.3 YEARS CONSIDERED 63
1.3.4 CURRENCY CONSIDERED 63
1.4 STAKEHOLDERS 63
2 EXECUTIVE SUMMARY 64
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 64
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 65
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 66
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 67
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 68
3 PREMIUM INSIGHTS 69
3.1 IN VITRO TOXICOLOGY TESTING MARKET OVERVIEW 69
3.2 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE 70
3.3 IN VITRO TOXICOLOGY TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 71
3.4 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET SHARE, BY END USER, 2026 VS 2031 (%) 71
4 MARKET OVERVIEW 72
4.1 INTRODUCTION 72
4.2 MARKET DYNAMICS 72
4.2.1 DRIVERS 74
4.2.1.1 Growing Industry Shift Toward Non-Animal Toxicology Testing Methods 74
4.2.1.2 Increasing Technological Advancements 74
4.2.1.3 Rising Pharmaceutical R&D Expenditure and Drug Attrition Costs 74
4.2.2 RESTRAINTS 75
4.2.2.1 Limited In Vivo-to-In Vitro Correlation for Complex Endpoints 75
4.2.2.2 High Cost of Advanced Platforms (Organ-on-Chip, 3D Models) 75
4.2.3 OPPORTUNITIES 75
4.2.3.1 AI/ML-Powered Predictive Toxicology 75
4.2.3.2 Increasing Focus on Drug Discovery Using In Vitro Methods 76
4.2.3.3 Cannabis, E-Cigarette, and Novel Product Safety Testing 76
4.2.4 CHALLENGES 76
4.2.4.1 Ethical and Regulatory Challenges in AI-Driven Toxicology 76
4.3 UNMET NEEDS AND WHITE SPACES 77
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 77
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 77
5 INDUSTRY TRENDS 79
5.1 PORTER’S FIVE FORCES ANALYSIS 79
5.1.1 THREAT OF NEW ENTRANTS 80
5.1.2 THREAT OF SUBSTITUTES 80
5.1.3 BARGAINING POWER OF BUYERS 80
5.1.4 BARGAINING POWER OF SUPPLIERS 80
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 80
5.2 MACROECONOMIC OUTLOOK 81
5.2.1 INTRODUCTION 81
5.2.2 GDP TRENDS AND FORECAST 81
5.2.3 TRENDS IN GLOBAL IN VITRO TOXICOLOGY TESTING MARKET 81
5.3 VALUE CHAIN ANALYSIS 82
5.4 ECOSYSTEM ANALYSIS 83
5.5 PRICING ANALYSIS 85
5.5.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, 2025 86
5.5.2 INDICATIVE SELLING PRICE, BY REGION, 2025 86
5.6 KEY CONFERENCES & EVENTS 87
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 87
5.8 INVESTMENT/FUNDING ACTIVITY 88
5.9 IMPACT OF 2025 TARIFFS—IN VITRO TOXICOLOGY TESTING MARKET 89
5.9.1 INTRODUCTION 89
5.9.2 KEY TARIFF RATES 89
5.9.3 PRICE IMPACT ANALYSIS 90
5.9.4 IMPACT ON COUNTRIES/REGIONS 90
5.9.4.1 North America 90
5.9.4.2 Europe 91
5.9.4.3 Asia Pacific 91
5.9.5 IMPACT ON END-USE INDUSTRIES 91
5.9.5.1 Pharmaceutical and biotechnology companies 92
5.9.5.2 CROs 92
5.9.5.3 Academic & Research Institutes 92
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 93
6.1 KEY TECHNOLOGIES 93
6.1.1 CELL CULTURE TECHNOLOGIES 93
6.1.2 OMICS TECHNOLOGIES 93
6.2 ADJACENT TECHNOLOGIES 94
6.2.1 COMPUTATIONAL TOXICOLOGY AND AI 94
6.3 COMPLEMENTARY TECHNOLOGIES 94
6.3.1 LAB-ON-A-CHIP (LOC)/ORGAN-ON-A-CHIP (OOC) SYSTEMS 94
6.4 TECHNOLOGY/PRODUCT ROADMAP 95
6.5 PATENT ANALYSIS 95
6.5.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR IN VITRO TOXICOLOGY TESTING PATENTS, 2015–2025 96
6.6 FUTURE APPLICATIONS 97
6.7 IMPACT OF AI/GEN AI ON IN VITRO TOXICOLOGY TESTING MARKET 97
6.7.1 TOP USE CASES AND MARKET POTENTIAL 98
6.7.2 CASE STUDIES OF AI IMPLEMENTATION IN IN VITRO TOXICOLOGY TESTING MARKET 99
6.7.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 99
6.7.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN IN VITRO TOXICOLOGY TESTING MARKET 99
7 SUSTAINABILITY AND REGULATORY LANDSCAPE 102
7.1 REGIONAL REGULATIONS AND COMPLIANCE 102
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102
7.1.2 REGULATORY FRAMEWORK 105
7.1.3 INDUSTRY STANDARDS 106
7.2 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 107
7.3 CERTIFICATIONS, LABELING, & ECO-STANDARDS 108
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 110
8.1 DECISION-MAKING PROCESS 110
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 110
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 110
8.2.2 KEY BUYING CRITERIA, BY END USER 111
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 112
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 113
8.5 MARKET PROFITABILITY 113
9 IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING 114
9.1 INTRODUCTION 115
9.2 PRODUCTS 115
9.2.1 GROWING ADOPTION OF ADVANCED ASSAY PRODUCTS TO SUPPORT GROWTH 115
9.3 SERVICES 119
9.3.1 INCREASING FOCUS ON OUTSOURCING TOXICOLOGY TO AID GROWTH 119
10 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE 123
10.1 INTRODUCTION 124
10.2 REAGENTS & CONSUMABLES 124
10.2.1 CULTURE REAGENTS, MEDIA, AND CONSUMABLES 127
10.2.1.1 Increasing adoption of IVTT workflows and recurring use of reagents to support growth 127
10.2.2 3D MODELS & TISSUE SYSTEMS 131
10.2.2.1 Support from regulatory agencies and wide usage to drive market growth 131
10.2.3 CELL LINES & PRIMARY CELLS 134
10.2.3.1 Emphasis on personalized medicine and driving quality improvement in commercially available cells to propel market 134
10.2.4 OTHER REAGENTS & CONSUMABLES 137
10.3 ASSAY KITS 140
10.3.1 ORGAN-SPECIFIC TOXICITY ASSAYS 143
10.3.1.1 Market is driven well-documented failure of generic cytotoxicity screens to predict organ-level adverse effects 143
10.3.2 CYTOTOXICITY ASSAYS 146
10.3.2.1 Cytotoxicity assays are the most universally applied assays in IVTT 146
10.3.3 GENOTOXICITY ASSAYS 149
10.3.3.1 Stringent regulatory mandates to support growth 149
10.3.4 OTHER ASSAYS 152
10.4 EQUIPMENT 155
10.4.1 DETECTION, IMAGING, AND ANALYTICAL SYSTEMS 158
10.4.1.1 Detection instruments 161
10.4.1.1.1 Growth is supported by the increasing volume of HTS workflows in pharmaceutical R&D and expanding use of functional safety pharmacology assays 161
10.4.1.2 Imaging systems 164
10.4.1.2.1 Demand for imaging systems in IVTT is being driven by the transition from single-endpoint to multiparametric, image-based toxicity assessment 164
10.4.1.3 Other instruments 168
10.4.1.4 Liquid handling & automation systems 171
10.4.1.4.1 Ease offered by automation and the important role of liquid handling in workflow to aid growth 171
10.4.1.5 Other instruments 174
10.5 SOFTWARE & INFORMATICS 177
10.5.1 DEMAND FOR AI/ML CAPABILITIES WITH TOXICOLOGY DATA TO DRIVE GROWTH 177
11 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TOXICITY ENDPOINT & TEST 181
11.1 INTRODUCTION 182
11.2 ORGAN TOXICITY TESTING 182
11.2.1 HEPATOTOXICITY 185
11.2.1.1 Regulatory mandates and focus on developing advanced liver models to support growth 185
11.2.2 OCULAR TOXICITY 189
11.2.2.1 Demand for cosmetics application to aid growth 189
11.2.3 CARDIOTOXICITY 192
11.2.3.1 Regulatory imperative for comprehensive cardiac safety profiling to drive growth 192
11.2.4 NEUROTOXICITY 195
11.2.4.1 Focus on developmental neurotoxicity and the expanding CNS drug pipelines to support growth 195
11.2.5 OTHER TOXICITY END POINTS 198
11.3 CYTOTOXICITY TESTING 201
11.3.1 A GROWING NUMBER OF NEW CLINICAL ENTITIES AND THE EXPANSION OF HTS PROGRAMS DRIVES MARKET 201
11.4 DERMAL TOXICITY & SKIN IRRITATION, CORROSION, AND SENSITIZATION 204
11.4.1 RISING AWARENESS AND BAN ON ANIMAL TESTING TO PROPEL MARKET 204
11.5 GENOTOXICITY TESTING 207
11.5.1 MANDATORY REQUIREMENT IN DRUG APPLICATIONS SUPPORTS MARKET GROWTH 207
11.6 OXIDATIVE STRESS AND MECHANISTIC TOXICITY 210
11.6.1 SHIFT TOWARD MECHANISTIC UNDERSTANDING TO DRIVE DEMAND FOR ASSAYS 210
11.7 OTHER TOXICITY ENDPOINTS & TESTS 213
12 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TECHNOLOGY 216
12.1 INTRODUCTION 217
12.2 CELL CULTURE TECHNOLOGIES 217
12.2.1 ADVANCING ADOPTION OF HUMAN-RELEVANT CELL CULTURE MODELS TO SUPPORT MARKET GROWTH 217
12.3 HIGH-THROUGHPUT & HIGH-CONTENT TECHNOLOGIES 220
12.3.1 EXPANDING HIGH-THROUGHPUT TOXICITY SCREENING TO ACCELERATE EARLY SAFETY ASSESSMENT 220
12.4 ORGANOTYPIC & MICROPHYSIOLOGICAL-BASED TECHNOLOGIES 223
12.4.1 GROWING FOCUS ON HUMAN-RELEVANT TOXICITY PREDICTION TO SUPPORT GROWTH 223
12.5 OMICS TECHNOLOGIES 226
12.5.1 INCREASING INTEGRATION OF OMICS-BASED TOXICOLOGY TO IMPROVE MECHANISTIC RISK ASSESSMENT 226
12.6 OTHER TECHNOLOGIES 229
13 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY METHOD 232
13.1 INTRODUCTION 233
13.2 CELL-BASED TOXICITY TESTING 233
13.2.1 CELL-BASED TOXICITY TESTING HOLDS LARGEST MARKET SHARE 233
13.3 BIOCHEMICAL TOXICITY TESTING METHOD 237
13.3.1 SPEED AND REPRODUCIBILITY TO AID GROWTH 237
13.4 MOLECULAR & OMICS-BASED TOXICOLOGY METHOD 240
13.4.1 TRANSITION FROM SINGLE-ENDPOINT TO SYSTEMS-LEVEL TOXICOLOGICAL ASSESSMENT DRIVES DEMAND GROWTH 240
13.5 EX VIVO MODEL-BASED TOXICITY TESTING METHOD 243
13.5.1 INCREASING AVAILABILITY OF HUMAN DONOR TISSUE TO SUPPORT ADOPTION 243
13.6 IN SILICO/COMPUTATIONAL TOXICITY TESTING METHOD 247
13.6.1 ESCALATING COST AND TIME PRESSURES OF PHYSICAL TESTING TO AID GROWTH 247
13.7 OTHER METHODS 250
14 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY END USER 253
14.1 INTRODUCTION 254
14.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 254
14.2.1 RISING GLOBAL PHARMACEUTICAL R&D EXPENDITURE SUPPORTING DRUG DISCOVERY EFFORTS 254
14.3 CONSUMER CARE COMPANIES 258
14.3.1 ANIMAL TESTING BANS TO SUPPORT SEGMENT GROWTH 258
14.4 CROS 261
14.4.1 HIGH CAPITAL AND OPERATIONAL COSTS OF MAINTAINING ADVANCED TECHNOLOGIES SUPPORT OUTSOURCING TO CROS 261
14.5 ACADEMIC & RESEARCH INSTITUTES 265
14.5.1 INCREASING GOVERNMENT FUNDING FOR ALTERNATIVE TESTING RESEARCH TO AID GROWTH 265
14.6 FOOD & BEVERAGE COMPANIES 268
14.6.1 GROWTH OF FUNCTIONAL FOODS, PLANT-BASED PROTEINS, AND NOVEL INGREDIENTS DRIVES DEMAND FOR TESTING 268
14.7 OTHER END USERS 272
15 IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY TYPE 276
15.1 INTRODUCTION 277
15.2 TOXICOLOGY TESTING SERVICES 277
15.2.1 ORGAN-SPECIFIC TOXICITY SERVICES 280
15.2.1.1 High reliance on outsourced services and growing demand for cardiotoxicity testing to drive market 280
15.2.2 CYTOTOXICITY TESTING SERVICES 283
15.2.2.1 Growing preclinical pipelines requiring cytotoxicity testing to propel demand 283
15.2.3 GENOTOXICITY TESTING SERVICES 286
15.2.3.1 Expanding impurity testing obligations to drive market 286
15.2.4 OTHER TOXICITY TESTING SERVICES 289
15.3 BIOLOGICAL MODEL & ASSAY DEVELOPMENT SERVICES 292
15.3.1 STRONG GROWTH SUPPORTED BY RISING DEMAND FOR APPLICATION-SPECIFIC MODELS AND ASSAYS 292
15.4 IMAGING & ANALYTICAL TOXICOLOGY SERVICES 295
15.4.1 CAPITAL-INTENSIVE INSTRUMENTATION AND SPECIALIZED REQUIREMENTS SUPPORT OUTSOURCING 295
15.5 DATA ANALYSIS, BIOINFORMATICS, AND PREDICTIVE TOXICOLOGY 298
15.5.1 INTEGRATION OF AI/ML AND RISING DATA COMPLEXITY PROPEL DEMAND 298
16 IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY METHOD 302
16.1 INTRODUCTION 303
16.2 CELL-BASED TOXICITY TESTING SERVICES 303
16.2.1 HIGH COST AND COMPLEXITY OF MAINTAINING ADVANCED CELL CULTURE INFRASTRUCTURE TO DRIVE GROWTH 303
16.3 BIOCHEMICAL TOXICITY TESTING SERVICES 307
16.3.1 GROWTH OF BIOLOGIC DRUG DEVELOPMENT IS DRIVING DEMAND FOR SPECIALIZED BIOCHEMICAL IMMUNOGENICITY TESTING SERVICES 307
16.4 IN SILICO/COMPUTATIONAL TOXICITY TESTING SERVICES 310
16.4.1 GROWING DATA COMPLEXITY, AI/ML MATURITY, AND REGULATORY ACCEPTANCE DRIVE GROWTH 310
16.5 MOLECULAR & OMICS-BASED TOXICOLOGY SERVICES 313
16.5.1 SPECIALIZED ANALYTICAL EXPERTISE REQUIREMENTS RELATED TO OMICS TO DRIVE GROWTH 313
16.6 EX VIVO MODEL-BASED TOXICITY TESTING SERVICES 317
16.6.1 USE OF EX VIVO MODELS FOR IN VITRO AND IN SILICO VALIDATION TO SUPPORT GROWTH 317
16.7 OTHER SERVICES 320
17 IN VITRO TOXICOLOGY TESTING SERVICE MARKET, BY END USER 323
17.1 INTRODUCTION 324
17.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 324
17.2.1 INCREASING COST AND COMPLEXITY OF MAINTAINING ADVANCED IVTT PLATFORMS IN-HOUSE TO SUPPORT GROWTH 324
17.3 CONSUMER CARE COMPANIES 328
17.3.1 REGULATION MANDATING IN VITRO-ONLY SAFETY ASSESSMENT IS SUPPORTING GROWTH 328
17.4 FOOD & BEVERAGE COMPANIES 331
17.4.1 EXPANDING SCOPE OF FUNCTIONAL FOOD AND ALTERNATIVE PROTEIN SAFETY ASSESSMENT TO SUPPORT GROWTH 331
17.5 ACADEMIC & RESEARCH INSTITUTES 335
17.5.1 OUTSOURCING OF SPECIALIZED SERVICES TO SUPPORT GROWTH 335
17.6 OTHER END USERS 338
18 IN VITRO TOXICOLOGY TESTING MARKET, BY REGION 342
18.1 INTRODUCTION 343
18.2 NORTH AMERICA 343
18.2.1 US 351
18.2.1.1 Growing focus on biomarker discovery and research in structure-based drug design to propel the market 351
18.2.2 CANADA 359
18.2.2.1 Strong support for R&D in pharmaceuticals and proteomics to boost market growth 359
18.3 EUROPE 367
18.3.1 GERMANY 374
18.3.1.1 Well-established pharmaceuticals industry to support market growth 374
18.3.2 UK 382
18.3.2.1 Rising focus on research activities and academia-industry partnerships to drive market 382
18.3.3 FRANCE 390
18.3.3.1 Increasing government funding for proteomics and genomics research to drive market 390
18.3.4 ITALY 398
18.3.4.1 Increasing life sciences research to propel market 398
18.3.5 SPAIN 405
18.3.5.1 Growing chemicals industry to support market growth 405
18.3.6 REST OF EUROPE 413
18.4 ASIA PACIFIC 420
18.4.1 CHINA 429
18.4.1.1 Increasing international pressure to ban animal testing methods to propel the market 429
18.4.2 JAPAN 436
18.4.2.1 Rising demand for technologically advanced research products to drive market 436
18.4.3 INDIA 443
18.4.3.1 Growing focus of universities on avoiding animal testing for cosmetic products to propel the market 443
18.4.4 SOUTH KOREA 451
18.4.4.1 Growing government focus on boosting pharmaceutical spending to propel market growth 451
18.4.5 AUSTRALIA 458
18.4.5.1 Growing pharmaceutical research to help market growth 458
18.4.6 REST OF ASIA PACIFIC 464
18.5 LATIN AMERICA 471
18.5.1 BRAZIL 479
18.5.1.1 Adoption of non-animal testing methods to propel market 479
18.5.2 MEXICO 486
18.5.2.1 Ban on animal testing for cosmetics to support market growth 486
18.5.3 REST OF LATIN AMERICA 493
18.6 MIDDLE EAST 500
18.6.1 GCC COUNTRIES 507
18.6.1.1 Saudi Arabia 515
18.6.1.1.1 Rising pharmaceutical R&D activities and regulatory focus on alternative testing methods to support market growth 515
18.6.1.2 United Arab Emirates (UAE) 522
18.6.1.2.1 Expanding biotechnology ecosystem and growing focus on advanced safety assessment technologies supporting market growth 522
18.6.1.3 Rest of GCC Countries 529
18.6.1.4 Rest of Middle East 536
18.6.2 AFRICA 543
18.6.2.1 Precision medicine initiatives to fuel market growth 543
19 COMPETITIVE LANDSCAPE 550
19.1 OVERVIEW 550
19.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 550
19.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN IN VITRO TOXICOLOGY TESTING MARKET 550
19.3 REVENUE SHARE ANALYSIS 552
19.4 MARKET SHARE ANALYSIS 553
19.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 555
19.5.1 STARS 555
19.5.2 EMERGING LEADERS 555
19.5.3 PERVASIVE PLAYERS 556
19.5.4 PARTICIPANTS 556
19.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 557
19.5.5.1 Company footprint 557
19.5.5.2 Region footprint 558
19.5.5.3 Offering footprint 559
19.5.5.4 Technology footprint 560
19.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 561
19.6.1 PROGRESSIVE COMPANIES 561
19.6.2 STARTING BLOCKS 561
19.6.3 RESPONSIVE COMPANIES 561
19.6.4 DYNAMIC COMPANIES 561
19.6.5 COMPETITIVE BENCHMARKING OF KEY STARTUP/SME PLAYERS 563
19.6.5.1 Competitive benchmarking of key startups/SMEs 564
19.7 COMPANY VALUATION & FINANCIAL METRICS 565
19.7.1 FINANCIAL METRICS 565
19.7.2 COMPANY VALUATION 565
19.8 BRAND/PRODUCT COMPARISON 566
19.9 COMPETITIVE SCENARIO 567
19.9.1 PRODUCT LAUNCHES 567
19.9.2 DEALS 568
19.9.3 EXPANSIONS 568
20 COMPANY PROFILES 569
20.1 THERMO FISHER SCIENTIFIC INC. 569
20.1.1 BUSINESS OVERVIEW 569
20.1.1.1 Products/Services/Solutions offered 570
20.1.1.2 Recent developments 574
20.1.1.2.1 Product launches 574
20.1.1.2.2 Deals 575
20.1.1.2.3 Expansions 575
20.1.1.3 MnM view 576
20.1.1.3.1 Key strengths 576
20.1.1.3.2 Strategic choices 576
20.1.1.3.3 Weaknesses and competitive threats 576
20.1.2 AGILENT TECHNOLOGIES, INC. 577
20.1.2.1 Business overview 577
20.1.2.2 Products/Services/Solutions offered 578
20.1.2.3 Recent developments 580
20.1.2.3.1 Product launches & enhancements 580
20.1.2.3.2 Deals 581
20.1.2.4 MnM view 581
20.1.2.4.1 Key strengths 581
20.1.2.4.2 Strategic choices 581
20.1.2.4.3 Weaknesses and competitive threats 581
20.1.3 MERCK KGAA 582
20.1.3.1 Business overview 582
20.1.3.2 Products/Services/Solutions offered 583
20.1.3.3 Recent developments 585
20.1.3.3.1 Deals 585
20.1.3.4 MnM view 585
20.1.3.4.1 Key strengths 585
20.1.3.4.2 Strategic choices 585
20.1.3.4.3 Weaknesses and competitive threats 585
20.1.4 EUROFINS SCIENTIFIC 586
20.1.4.1 Business overview 586
20.1.4.2 Products/Services/Solutions offered 587
20.1.4.3 Recent developments 594
20.1.4.3.1 Expansions 594
20.1.5 CHARLES RIVER LABORATORIES 595
20.1.5.1 Business overview 595
20.1.5.2 Products/Services/Solutions offered 596
20.1.5.3 Recent developments 600
20.1.5.3.1 Product launches 600
20.1.5.3.2 Deals 600
20.1.5.3.3 Other developments 601
20.1.5.4 MnM view 601
20.1.5.4.1 Key strengths 601
20.1.5.4.2 Strategic choices 601
20.1.5.4.3 Weaknesses and competitive threats 601
20.1.6 LABORATORY CORPORATION OF AMERICA HOLDINGS 602
20.1.6.1 Business overview 602
20.1.6.2 Products/Services/Solutions offered 603
20.1.6.3 Recent developments 606
20.1.6.3.1 Deals 606
20.1.6.3.2 Expansions 606
20.1.6.3.3 Other developments 607
20.1.6.4 MnM view 607
20.1.6.4.1 Key strengths 607
20.1.6.4.2 Strategic choices 607
20.1.6.4.3 Weaknesses and competitive threats 607
20.1.7 SGS SA 608
20.1.7.1 Business overview 608
20.1.7.2 Products/Services/Solutions offered 609
20.1.7.3 Recent developments 612
20.1.7.3.1 Deals 612
20.1.7.3.2 Expansions 612
20.1.8 LONZA 613
20.1.8.1 Business overview 613
20.1.8.2 Products/Services/Solutions offered 614
20.1.9 REVVITY 616
20.1.9.1 Business overview 616
20.1.9.2 Products/Services/Solutions offered 617
20.1.9.3 Recent developments 619
20.1.9.3.1 Product launches 619
20.1.9.3.2 Other developments 619
20.1.10 BIO-RAD LABORATORIES, INC. 620
20.1.10.1 Business overview 620
20.1.10.2 Products/Services/Solutions offered 621
20.1.10.3 Recent developments 623
20.1.10.3.1 Product launches 623
20.1.10.3.2 Deals 624
20.1.11 EVOTEC SE 625
20.1.11.1 Business overview 625
20.1.11.2 Products/Services/Solutions offered 626
20.1.11.3 Recent developments 633
20.1.11.3.1 Deals 633
20.1.11.3.2 Other developments 633
20.1.12 NOVO HOLDINGS 634
20.1.12.1 Business overview 634
20.1.12.2 Products & services offered 634
20.1.13 INTERTEK GROUP PLC 635
20.1.13.1 Business overview 635
20.1.13.2 Products & services offered 637
20.1.14 INOTIV 638
20.1.14.1 Business overview 638
20.1.14.2 Products & services offered 639
20.1.15 PROMEGA CORPORATION 642
20.1.15.1 Business overview 642
20.1.15.2 Products & services offered 642
20.1.15.3 Recent developments 645
20.1.15.3.1 Deals 645
20.2 OTHER PLAYERS 646
20.2.1 BIOIVT 646
20.2.2 CREATIVE BIOLABS 647
20.2.3 MEDICILON 648
20.2.4 CREATIVE BIOARRAY 649
20.2.5 ARAGEN LIFE SCIENCES LTD. 650
20.2.6 ENZO BIOCHEM INC. 652
20.2.7 MICROBAC LABORATORIES, INC. 655
20.2.8 VIMTA LABS LTD. 657
20.2.9 PACIFIC BIOLABS, INC. 658
20.2.10 MB RESEARCH LABORATORIES 659
21 RESEARCH METHODOLOGY 660
21.1 RESEARCH DATA 660
21.1.1 SECONDARY DATA 661
21.1.2 PRIMARY DATA 661
21.2 MARKET SIZE ESTIMATION 662
21.2.1 GLOBAL IN VITRO TOXICOLOGY TESTING MARKET ESTIMATION, 2025 662
21.2.1.1 Key industry insights 666
21.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 667
21.4 MARKET BREAKDOWN AND DATA TRIANGULATION 670
21.5 RESEARCH ASSUMPTIONS 671
21.6 RESEARCH LIMITATIONS 672
21.7 RISK ANALYSIS 672
22 APPENDIX 673
22.1 DISCUSSION GUIDE 673
22.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 678
22.3 CUSTOMIZATION OPTIONS 680
22.4 RELATED REPORTS 680
22.5 AUTHOR DETAILS 681

ページTOPに戻る

List of Tables/Graphs

TABLE 1 IN VITRO TOXICOLOGY TESTING MARKET: IMPACT ANALYSIS 73
TABLE 2 IN VITRO TOXICOLOGY TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 80
TABLE 3 IN VITRO TOXICOLOGY TESTING MARKET: ROLE IN ECOSYSTEM 84
TABLE 4 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT 86
TABLE 5 INDICATIVE SELLING PRICE, BY REGION, 2025 86
TABLE 6 IN VITRO TOXICOLOGY TESTING MARKET: KEY CONFERENCES & EVENTS,
2026–2027 87
TABLE 7 US-ADJUSTED RECIPROCAL TARIFF RATES 89
TABLE 8 INDICATIVE LIST OF PATENTS IN IN VITRO TOXICOLOGY TESTING MARKET, 2026 97
TABLE 9 CASE STUDIES OF AI IMPLEMENTATION IN IN VITRO TOXICOLOGY TESTING MARKET 99
TABLE 10 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN IN VITRO TOXICOLOGY
TESTING MARKET 100
TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 102
TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 103
TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 104
TABLE 14 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 104
TABLE 15 COUNTRY-WISE REGULATORY SCENARIO FOR IN VITRO TOXICOLOGY TESTING PRODUCT & SERVICE PROVIDERS 105
TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING (%) 111
TABLE 17 KEY BUYING CRITERIA, BY END USER 111
TABLE 18 IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING,
2024–2031(USD MILLION) 115
TABLE 19 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY REGION,
2024–2031(USD MILLION) 116
TABLE 20 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031(USD MILLION) 116
TABLE 21 EUROPE: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031(USD MILLION) 117
TABLE 22 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY COUNTRY, 2024–2031(USD MILLION) 117
TABLE 23 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031(USD MILLION) 118
TABLE 24 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY REGION, 2024–2031(USD MILLION) 118
TABLE 25 GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET,
BY COUNTRY, 2024–2031(USD MILLION) 118
TABLE 26 IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY REGION,
2024–2031(USD MILLION) 120
TABLE 27 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY COUNTRY, 2024–2031(USD MILLION) 120
TABLE 28 EUROPE: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031(USD MILLION) 121
TABLE 29 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031(USD MILLION) 121
TABLE 30 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2024–2031(USD MILLION) 122
TABLE 31 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY REGION, 2024–2031(USD MILLION) 122
TABLE 32 GCC COUNTRIES: IN VITRO TOXICOLOGY TESTING SERVICES MARKET,
BY COUNTRY, 2024–2031(USD MILLION) 122
TABLE 33 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 124
TABLE 34 IVTT REAGENTS & CONSUMABLES MARKET, BY REGION,
2024–2031 (USD MILLION) 125
TABLE 35 NORTH AMERICA: IVTT REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 125
TABLE 36 EUROPE: IVTT REAGENTS & CONSUMABLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 125
TABLE 37 ASIA PACIFIC: IVTT REAGENTS & CONSUMABLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 126
TABLE 38 LATIN AMERICA: IVTT REAGENTS & CONSUMABLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 126
TABLE 39 MIDDLE EAST: IVTT REAGENTS & CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION) 126
TABLE 40 GCC COUNTRIES: IVTT REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 127
TABLE 41 IVTT REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 127
TABLE 42 CULTURE REAGENTS, MEDIA, AND CONSUMABLES MARKET, BY REGION,
2024–2031 (USD MILLION) 128
TABLE 43 NORTH AMERICA: CULTURE REAGENTS, MEDIA, AND CONSUMABLES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 128
TABLE 44 EUROPE: CULTURE REAGENTS, MEDIA, AND CONSUMABLES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 129
TABLE 45 ASIA PACIFIC: CULTURE REAGENTS, MEDIA, AND CONSUMABLES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 129
TABLE 46 LATIN AMERICA: CULTURE REAGENTS, MEDIA, AND CONSUMABLES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 47 MIDDLE EAST: CULTURE REAGENTS, MEDIA, AND CONSUMABLES MARKET,
BY REGION, 2024–2031 (USD MILLION) 130
TABLE 48 GCC COUNTRIES: CULTURE REAGENTS, MEDIA, AND CONSUMABLES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 49 3D MODELS & TISSUE SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 132
TABLE 50 NORTH AMERICA: 3D MODELS & TISSUE SYSTEMS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 132
TABLE 51 EUROPE: 3D MODELS & TISSUE SYSTEMS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 132
TABLE 52 ASIA PACIFIC: 3D MODELS & TISSUE SYSTEMS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 133
TABLE 53 LATIN AMERICA: 3D MODELS & TISSUE SYSTEMS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 133
TABLE 54 MIDDLE EAST: 3D MODELS & TISSUE SYSTEMS MARKET, BY REGION,
2024–2031 (USD MILLION) 133
TABLE 55 GCC COUNTRIES: 3D MODELS & TISSUE SYSTEMS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 134
TABLE 56 CELL LINES & PRIMARY CELLS MARKET, BY REGION, 2024–2031 (USD MILLION) 135
TABLE 57 NORTH AMERICA: CELL LINES & PRIMARY CELLS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 135
TABLE 58 EUROPE: CELL LINES & PRIMARY CELLS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 135
TABLE 59 ASIA PACIFIC: CELL LINES & PRIMARY CELLS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 136
TABLE 60 LATIN AMERICA: CELL LINES & PRIMARY CELLS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 136
TABLE 61 MIDDLE EAST: CELL LINES & PRIMARY CELLS MARKET, BY REGION,
2024–2031 (USD MILLION) 136
TABLE 62 GCC COUNTRIES: CELL LINES & PRIMARY CELLS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 137
TABLE 63 OTHER REAGENTS & CONSUMABLES MARKET, BY REGION,
2024–2031 (USD MILLION) 138
TABLE 64 NORTH AMERICA: OTHER REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 65 EUROPE: OTHER REAGENTS & CONSUMABLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 138
TABLE 66 ASIA PACIFIC: OTHER REAGENTS & CONSUMABLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 139
TABLE 67 LATIN AMERICA: OTHER REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 139
TABLE 68 MIDDLE EAST: OTHER REAGENTS & CONSUMABLES MARKET, BY REGION,
2024–2031 (USD MILLION) 139
TABLE 69 GCC COUNTRIES: OTHER REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140
TABLE 70 IVTT ASSAY KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 140
TABLE 71 NORTH AMERICA: IVTT ASSAY KITS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 140
TABLE 72 EUROPE: IVTT ASSAY KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 73 ASIA PACIFIC: IVTT ASSAY KITS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 141
TABLE 74 LATIN AMERICA: IVTT ASSAY KITS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 142
TABLE 75 MIDDLE EAST: IVTT ASSAY KITS MARKET, BY REGION, 2024–2031 (USD MILLION) 142
TABLE 76 GCC COUNTRIES: IVTT ASSAY KITS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 142
TABLE 77 IVTT ASSAY KITS MARKET, BY TYPE, 2024–2031 (USD MILLION) 143
TABLE 78 ORGAN-SPECIFIC TOXICITY ASSAYS MARKET, BY REGION,
2024–2031 (USD MILLION) 144
TABLE 79 NORTH AMERICA: ORGAN-SPECIFIC TOXICITY ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 80 EUROPE: ORGAN-SPECIFIC TOXICITY ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 144
TABLE 81 ASIA PACIFIC: ORGAN-SPECIFIC TOXICITY ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 145
TABLE 82 LATIN AMERICA: ORGAN-SPECIFIC TOXICITY ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 145
TABLE 83 MIDDLE EAST: ORGAN-SPECIFIC TOXICITY ASSAYS MARKET, BY REGION,
2024–2031 (USD MILLION) 145
TABLE 84 GCC COUNTRIES: ORGAN-SPECIFIC TOXICITY ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 146
TABLE 85 CYTOTOXICITY ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION) 147
TABLE 86 NORTH AMERICA: CYTOTOXICITY ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 147
TABLE 87 EUROPE: CYTOTOXICITY ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 147
TABLE 88 ASIA PACIFIC: CYTOTOXICITY ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 148
TABLE 89 LATIN AMERICA: CYTOTOXICITY ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 148
TABLE 90 MIDDLE EAST: CYTOTOXICITY ASSAYS MARKET, BY REGION,
2024–2031 (USD MILLION) 148
TABLE 91 GCC COUNTRIES: CYTOTOXICITY ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 149
TABLE 92 GENOTOXICITY ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION) 150
TABLE 93 NORTH AMERICA: GENOTOXICITY ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 150
TABLE 94 EUROPE: GENOTOXICITY ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 150
TABLE 95 ASIA PACIFIC: GENOTOXICITY ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 151
TABLE 96 LATIN AMERICA: GENOTOXICITY ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 151
TABLE 97 MIDDLE EAST: GENOTOXICITY ASSAYS MARKET, BY REGION,
2024–2031 (USD MILLION) 151
TABLE 98 GCC COUNTRIES: GENOTOXICITY ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 152
TABLE 99 OTHER ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION) 153
TABLE 100 NORTH AMERICA: OTHER ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 153
TABLE 101 EUROPE: OTHER ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 153
TABLE 102 ASIA PACIFIC: OTHER ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 103 LATIN AMERICA: OTHER ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 154
TABLE 104 MIDDLE EAST: OTHER ASSAYS MARKET, BY REGION, 2024–2031 (USD MILLION) 154
TABLE 105 GCC COUNTRIES: OTHER ASSAYS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 155
TABLE 106 IVTT EQUIPMENT MARKET, BY REGION, 2024–2031 (USD MILLION) 155
TABLE 107 NORTH AMERICA: IVTT EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 155
TABLE 108 EUROPE: IVTT EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 156
TABLE 109 ASIA PACIFIC: IVTT EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 156
TABLE 110 LATIN AMERICA: IVTT EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 157
TABLE 111 MIDDLE EAST: IVTT EQUIPMENT MARKET, BY REGION, 2024–2031 (USD MILLION) 157
TABLE 112 GCC COUNTRIES: IVTT EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 157
TABLE 113 IVTT EQUIPMENT MARKET, BY TYPE, 2024–2031 (USD MILLION) 158
TABLE 114 DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET, BY REGION,
2024–2031 (USD MILLION) 158
TABLE 115 NORTH AMERICA: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 159
TABLE 116 EUROPE: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 159
TABLE 117 ASIA PACIFIC: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 160
TABLE 118 LATIN AMERICA: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 160
TABLE 119 MIDDLE EAST: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET,
BY REGION, 2024–2031 (USD MILLION) 160
TABLE 120 GCC COUNTRIES: DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 161
TABLE 121 DETECTION, IMAGING, AND ANALYTICAL SYSTEMS MARKET, BY TYPE,
2024–2031 (USD MILLION) 161
TABLE 122 DETECTION INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 162
TABLE 123 NORTH AMERICA: DETECTION INSTRUMENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 162
TABLE 124 EUROPE: DETECTION INSTRUMENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 162
TABLE 125 ASIA PACIFIC: DETECTION INSTRUMENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 163
TABLE 126 LATIN AMERICA: DETECTION INSTRUMENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 163
TABLE 127 MIDDLE EAST: DETECTION INSTRUMENTS MARKET, BY REGION,
2024–2031 (USD MILLION) 163
TABLE 128 GCC COUNTRIES: DETECTION INSTRUMENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 164
TABLE 129 IMAGING SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 165
TABLE 130 NORTH AMERICA: IMAGING SYSTEMS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 165
TABLE 131 EUROPE: IMAGING SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 132 ASIA PACIFIC: IMAGING SYSTEMS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 166
TABLE 133 LATIN AMERICA: IMAGING SYSTEMS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 167
TABLE 134 MIDDLE EAST: IMAGING SYSTEMS MARKET, BY REGION,
2024–2031 (USD MILLION) 167
TABLE 135 GCC COUNTRIES: IMAGING SYSTEMS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 167
TABLE 136 OTHER INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 168
TABLE 137 NORTH AMERICA: OTHER INSTRUMENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 168
TABLE 138 EUROPE: OTHER INSTRUMENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 169
TABLE 139 ASIA PACIFIC: OTHER INSTRUMENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 169
TABLE 140 LATIN AMERICA: OTHER INSTRUMENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 170
TABLE 141 MIDDLE EAST: OTHER INSTRUMENTS MARKET, BY REGION,
2024–2031 (USD MILLION) 170
TABLE 142 GCC COUNTRIES: OTHER INSTRUMENTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 170
TABLE 143 LIQUID HANDLING & AUTOMATION SYSTEMS MARKET, BY REGION,
2024–2031 (USD MILLION) 171
TABLE 144 NORTH AMERICA: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 145 EUROPE: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 146 ASIA PACIFIC: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 147 LATIN AMERICA: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 148 MIDDLE EAST: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 173
TABLE 149 GCC COUNTRIES: LIQUID HANDLING & AUTOMATION SYSTEMS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 150 OTHER INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 174
TABLE 151 NORTH AMERICA: OTHER EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 175
TABLE 152 EUROPE: OTHER EQUIPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 153 ASIA PACIFIC: OTHER EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 176
TABLE 154 LATIN AMERICA: OTHER EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 176
TABLE 155 MIDDLE EAST: OTHER EQUIPMENT MARKET, BY REGION,
2024–2031 (USD MILLION) 176
TABLE 156 GCC COUNTRIES: OTHER EQUIPMENT MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 177
TABLE 157 IVTT SOFTWARE & INFORMATICS MARKET, BY REGION,
2024–2031 (USD MILLION) 178
TABLE 158 NORTH AMERICA: IVTT SOFTWARE & INFORMATICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 178
TABLE 159 EUROPE: IVTT SOFTWARE & INFORMATICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 179
TABLE 160 ASIA PACIFIC: IVTT SOFTWARE & INFORMATICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 179
TABLE 161 LATIN AMERICA: IVTT SOFTWARE & INFORMATICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 180
TABLE 162 MIDDLE EAST: IVTT SOFTWARE & INFORMATICS MARKET, BY REGION,
2024–2031 (USD MILLION) 180
TABLE 163 GCC COUNTRIES: IVTT SOFTWARE & INFORMATICS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 180
TABLE 164 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TOXICITY ENDPOINT & TEST, 2024–2031 (USD MILLION) 182
TABLE 165 ORGAN TOXICITY TESTING MARKET, BY REGION, 2024–2031 (USD MILLION) 183
TABLE 166 NORTH AMERICA: ORGAN TOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 183
TABLE 167 EUROPE: ORGAN TOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 183
TABLE 168 ASIA PACIFIC: ORGAN TOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 184
TABLE 169 LATIN AMERICA: ORGAN TOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 184
TABLE 170 MIDDLE EAST: ORGAN TOXICITY TESTING MARKET, BY REGION,
2024–2031 (USD MILLION) 184
TABLE 171 GCC COUNTRIES: ORGAN TOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 185
TABLE 172 ORGAN TOXICITY TESTING MARKET, BY TYPE, 2024–2031 (USD MILLION) 185
TABLE 173 HEPATOTOXICITY MARKET, BY REGION, 2024–2031 (USD MILLION) 186
TABLE 174 NORTH AMERICA: HEPATOTOXICITY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 186
TABLE 175 EUROPE: HEPATOTOXICITY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 187
TABLE 176 ASIA PACIFIC: HEPATOTOXICITY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 187
TABLE 177 LATIN AMERICA: HEPATOTOXICITY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 188
TABLE 178 MIDDLE EAST: HEPATOTOXICITY MARKET, BY REGION, 2024–2031 (USD MILLION) 188
TABLE 179 GCC COUNTRIES: HEPATOTOXICITY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 188
TABLE 180 OCULAR TOXICITY MARKET, BY REGION, 2024–2031 (USD MILLION) 189
TABLE 181 NORTH AMERICA: OCULAR TOXICITY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 189
TABLE 182 EUROPE: OCULAR TOXICITY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 183 ASIA PACIFIC: OCULAR TOXICITY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 190
TABLE 184 LATIN AMERICA: OCULAR TOXICITY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 191
TABLE 185 MIDDLE EAST: OCULAR TOXICITY MARKET, BY REGION,
2024–2031 (USD MILLION) 191
TABLE 186 GCC COUNTRIES: OCULAR TOXICITY MARKET, BY COUNTRY
, 2024–2031 (USD MILLION) 191
TABLE 187 CARDIOTOXICITY MARKET, BY REGION, 2024–2031 (USD MILLION) 192
TABLE 188 NORTH AMERICA: CARDIOTOXICITY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 192
TABLE 189 EUROPE: CARDIOTOXICITY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 190 ASIA PACIFIC: CARDIOTOXICITY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 193
TABLE 191 LATIN AMERICA: CARDIOTOXICITY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 194
TABLE 192 MIDDLE EAST: CARDIOTOXICITY MARKET, BY REGION, 2024–2031 (USD MILLION) 194
TABLE 193 GCC COUNTRIES: CARDIOTOXICITY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 194
TABLE 194 NEUROTOXICITY MARKET, BY REGION, 2024–2031 (USD MILLION) 195
TABLE 195 NORTH AMERICA: NEUROTOXICITY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 195
TABLE 196 EUROPE: NEUROTOXICITY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 196
TABLE 197 ASIA PACIFIC: NEUROTOXICITY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 196
TABLE 198 LATIN AMERICA: NEUROTOXICITY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 197
TABLE 199 MIDDLE EAST: NEUROTOXICITY MARKET, BY REGION, 2024–2031 (USD MILLION) 197
TABLE 200 GCC COUNTRIES: NEUROTOXICITY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 197
TABLE 201 OTHER TOXICITY END POINTS MARKET, BY REGION, 2024–2031 (USD MILLION) 198
TABLE 202 NORTH AMERICA: OTHER TOXICITY END POINTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 198
TABLE 203 EUROPE: OTHER TOXICITY END POINTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 199
TABLE 204 ASIA PACIFIC: OTHER TOXICITY END POINTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 199
TABLE 205 LATIN AMERICA: OTHER TOXICITY END POINTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 200
TABLE 206 MIDDLE EAST: OTHER TOXICITY END POINTS MARKET, BY REGION,
2024–2031 (USD MILLION) 200
TABLE 207 GCC COUNTRIES: OTHER TOXICITY END POINTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 200
TABLE 208 CYTOTOXICITY TESTING MARKET, BY REGION, 2024–2031 (USD MILLION) 201
TABLE 209 NORTH AMERICA: CYTOTOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 201
TABLE 210 EUROPE: CYTOTOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 202
TABLE 211 ASIA PACIFIC: CYTOTOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 202
TABLE 212 LATIN AMERICA: CYTOTOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 203
TABLE 213 MIDDLE EAST: CYTOTOXICITY TESTING MARKET, BY REGION,
2024–2031 (USD MILLION) 203
TABLE 214 GCC COUNTRIES: CYTOTOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 203
TABLE 215 DERMAL TOXICITY & SKIN IRRITATION, CORROSION, AND SENSITIZATION MARKET, BY REGION, 2024–2031 (USD MILLION) 204
TABLE 216 NORTH AMERICA: DERMAL TOXICITY & SKIN IRRITATION, CORROSION, AND SENSITIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 204
TABLE 217 EUROPE: DERMAL TOXICITY & SKIN IRRITATION, CORROSION, AND SENSITIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 218 ASIA PACIFIC: DERMAL TOXICITY & SKIN IRRITATION, CORROSION, AND SENSITIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 219 LATIN AMERICA: DERMAL TOXICITY & SKIN IRRITATION, CORROSION, AND SENSITIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 206
TABLE 220 MIDDLE EAST: DERMAL TOXICITY & SKIN IRRITATION, CORROSION, AND SENSITIZATION MARKET, BY REGION, 2024–2031 (USD MILLION) 206
TABLE 221 GCC COUNTRIES: DERMAL TOXICITY & SKIN IRRITATION, CORROSION, AND SENSITIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 206
TABLE 222 GENOTOXICITY TESTING MARKET, BY REGION, 2024–2031 (USD MILLION) 207
TABLE 223 NORTH AMERICA: GENOTOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 207
TABLE 224 EUROPE: GENOTOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 208
TABLE 225 ASIA PACIFIC: GENOTOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 208
TABLE 226 LATIN AMERICA: GENOTOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 209
TABLE 227 MIDDLE EAST: GENOTOXICITY TESTING MARKET, BY REGION,
2024–2031 (USD MILLION) 209
TABLE 228 GCC COUNTRIES: GENOTOXICITY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 209
TABLE 229 OXIDATIVE STRESS AND MECHANISTIC TOXICITY MARKET, BY REGION,
2024–2031 (USD MILLION) 210
TABLE 230 NORTH AMERICA: OXIDATIVE STRESS AND MECHANISTIC TOXICITY MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 210
TABLE 231 EUROPE: OXIDATIVE STRESS AND MECHANISTIC TOXICITY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 211
TABLE 232 ASIA PACIFIC: OXIDATIVE STRESS AND MECHANISTIC TOXICITY MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 211
TABLE 233 LATIN AMERICA: OXIDATIVE STRESS AND MECHANISTIC TOXICITY MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 212
TABLE 234 MIDDLE EAST: OXIDATIVE STRESS AND MECHANISTIC TOXICITY MARKET,
BY REGION, 2024–2031 (USD MILLION) 212
TABLE 235 GCC COUNTRIES: OXIDATIVE STRESS AND MECHANISTIC TOXICITY MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 212
TABLE 236 OTHER TOXICITY ENDPOINTS & TESTS MARKET, BY REGION,
2024–2031 (USD MILLION) 213
TABLE 237 NORTH AMERICA: OTHER TOXICITY ENDPOINTS & TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 213
TABLE 238 EUROPE: OTHER TOXICITY ENDPOINTS & TESTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 214
TABLE 239 ASIA PACIFIC: OTHER TOXICITY ENDPOINTS & TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 214
TABLE 240 LATIN AMERICA: OTHER TOXICITY ENDPOINTS & TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 215
TABLE 241 MIDDLE EAST: OTHER TOXICITY ENDPOINTS & TESTS MARKET, BY REGION,
2024–2031 (USD MILLION) 215
TABLE 242 GCC COUNTRIES: OTHER TOXICITY ENDPOINTS & TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 215
TABLE 243 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TECHNOLOGY,
2024–2031 (USD MILLION) 217
TABLE 244 CELL CULTURE TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 218
TABLE 245 NORTH AMERICA: CELL CULTURE TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 218
TABLE 246 EUROPE: CELL CULTURE TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 218
TABLE 247 ASIA PACIFIC: CELL CULTURE TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 219
TABLE 248 LATIN AMERICA: CELL CULTURE TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 219
TABLE 249 MIDDLE EAST: CELL CULTURE TECHNOLOGIES MARKET, BY REGION,
2024–2031 (USD MILLION) 219
TABLE 250 GCC COUNTRIES: CELL CULTURE TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 220
TABLE 251 HIGH-THROUGHPUT & HIGH-CONTENT TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 220
TABLE 252 NORTH AMERICA: HIGH-THROUGHPUT & HIGH-CONTENT TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 253 EUROPE: HIGH-THROUGHPUT & HIGH-CONTENT TECHNOLOGIES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 254 ASIA PACIFIC: HIGH-THROUGHPUT & HIGH-CONTENT TECHNOLOGIES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 222
TABLE 255 LATIN AMERICA: HIGH-THROUGHPUT & HIGH-CONTENT TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 222
TABLE 256 MIDDLE EAST: HIGH-THROUGHPUT & HIGH-CONTENT TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 222
TABLE 257 GCC COUNTRIES: HIGH-THROUGHPUT & HIGH-CONTENT TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 223
TABLE 258 ORGANOTYPIC & MICROPHYSIOLOGICAL-BASED TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 223
TABLE 259 NORTH AMERICA: ORGANOTYPIC & MICROPHYSIOLOGICAL-BASED TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 224
TABLE 260 EUROPE: ORGANOTYPIC & MICROPHYSIOLOGICAL-BASED TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 224
TABLE 261 ASIA PACIFIC: ORGANOTYPIC & MICROPHYSIOLOGICAL-BASED TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 225
TABLE 262 LATIN AMERICA: ORGANOTYPIC & MICROPHYSIOLOGICAL-BASED TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 225
TABLE 263 MIDDLE EAST: ORGANOTYPIC & MICROPHYSIOLOGICAL-BASED TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 225
TABLE 264 GCC COUNTRIES: ORGANOTYPIC & MICROPHYSIOLOGICAL-BASED TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 226
TABLE 265 OMICS TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 226
TABLE 266 NORTH AMERICA: OMICS TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 227
TABLE 267 EUROPE: OMICS TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 227
TABLE 268 ASIA PACIFIC: OMICS TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 228
TABLE 269 LATIN AMERICA: OMICS TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 228
TABLE 270 MIDDLE EAST: OMICS TECHNOLOGIES MARKET, BY REGION,
2024–2031 (USD MILLION) 228
TABLE 271 GCC COUNTRIES: OMICS TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 229
TABLE 272 OTHER TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 229
TABLE 273 NORTH AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 230
TABLE 274 EUROPE: OTHER TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 230
TABLE 275 ASIA PACIFIC: OTHER TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 230
TABLE 276 LATIN AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 231
TABLE 277 MIDDLE EAST: OTHER TECHNOLOGIES MARKET, BY REGION,
2024–2031 (USD MILLION) 231
TABLE 278 GCC COUNTRIES: OTHER TECHNOLOGIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 231
TABLE 279 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY METHOD,
2024–2031 (USD MILLION) 233
TABLE 280 CELL-BASED TOXICITY TESTING METHOD MARKET, BY REGION,
2024–2031 (USD MILLION) 234
TABLE 281 NORTH AMERICA: CELL-BASED TOXICITY TESTING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 234
TABLE 282 EUROPE: CELL-BASED TOXICITY TESTING METHOD MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 235
TABLE 283 ASIA PACIFIC: CELL-BASED TOXICITY TESTING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 235
TABLE 284 LATIN AMERICA: CELL-BASED TOXICITY TESTING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 236
TABLE 285 MIDDLE EAST: CELL-BASED TOXICITY TESTING METHOD MARKET, BY REGION, 2024–2031 (USD MILLION) 236
TABLE 286 GCC COUNTRIES: CELL-BASED TOXICITY TESTING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 236
TABLE 287 BIOCHEMICAL TOXICITY TESTING METHOD MARKET, BY REGION,
2024–2031 (USD MILLION) 237
TABLE 288 NORTH AMERICA: BIOCHEMICAL TOXICITY TESTING METHOD MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 237
TABLE 289 EUROPE: BIOCHEMICAL TOXICITY TESTING METHOD MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 238
TABLE 290 ASIA PACIFIC: BIOCHEMICAL TOXICITY TESTING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 238
TABLE 291 LATIN AMERICA: BIOCHEMICAL TOXICITY TESTING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 239
TABLE 292 MIDDLE EAST: BIOCHEMICAL TOXICITY TESTING METHOD MARKET, BY REGION, 2024–2031 (USD MILLION) 239
TABLE 293 GCC COUNTRIES: BIOCHEMICAL TOXICITY TESTING METHOD MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 239
TABLE 294 MOLECULAR & OMICS-BASED TOXICOLOGY METHOD MARKET, BY REGION,
2024–2031 (USD MILLION) 240
TABLE 295 NORTH AMERICA: MOLECULAR & OMICS-BASED TOXICOLOGY METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 241
TABLE 296 EUROPE: MOLECULAR & OMICS-BASED TOXICOLOGY METHOD MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 241
TABLE 297 ASIA PACIFIC: MOLECULAR & OMICS-BASED TOXICOLOGY METHOD MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 242
TABLE 298 LATIN AMERICA: MOLECULAR & OMICS-BASED TOXICOLOGY METHOD MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 242
TABLE 299 MIDDLE EAST: MOLECULAR & OMICS-BASED TOXICOLOGY METHOD MARKET,
BY REGION, 2024–2031 (USD MILLION) 242
TABLE 300 GCC COUNTRIES: MOLECULAR & OMICS-BASED TOXICOLOGY METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 243
TABLE 301 EX VIVO MODEL-BASED TOXICITY TESTING METHOD MARKET, BY REGION,
2024–2031 (USD MILLION) 244
TABLE 302 NORTH AMERICA: EX VIVO MODEL-BASED TOXICITY TESTING METHOD MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 244
TABLE 303 EUROPE: EX VIVO MODEL-BASED TOXICITY TESTING METHOD MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 245
TABLE 304 ASIA PACIFIC: EX VIVO MODEL-BASED TOXICITY TESTING METHOD MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 245
TABLE 305 LATIN AMERICA: EX VIVO MODEL-BASED TOXICITY TESTING METHOD MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 246
TABLE 306 MIDDLE EAST: EX VIVO MODEL-BASED TOXICITY TESTING METHOD MARKET,
BY REGION, 2024–2031 (USD MILLION) 246
TABLE 307 GCC COUNTRIES: EX VIVO MODEL-BASED TOXICITY TESTING METHOD MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 246
TABLE 308 IN SILICO/COMPUTATIONAL TOXICITY TESTING METHOD MARKET, BY REGION, 2024–2031 (USD MILLION) 247
TABLE 309 NORTH AMERICA: IN SILICO/COMPUTATIONAL TOXICITY TESTING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 247
TABLE 310 EUROPE: IN SILICO/COMPUTATIONAL TOXICITY TESTING METHOD MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 248
TABLE 311 ASIA PACIFIC: IN SILICO/COMPUTATIONAL TOXICITY TESTING METHOD MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 248
TABLE 312 LATIN AMERICA: IN SILICO/COMPUTATIONAL TOXICITY TESTING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 249
TABLE 313 MIDDLE EAST: IN SILICO/COMPUTATIONAL TOXICITY TESTING METHOD MARKET, BY REGION, 2024–2031 (USD MILLION) 249
TABLE 314 GCC COUNTRIES: IN SILICO/COMPUTATIONAL TOXICITY TESTING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 249
TABLE 315 OTHER IN VITRO TOXICOLOGY TESTING METHODS MARKET, BY REGION,
2024–2031 (USD MILLION) 250
TABLE 316 NORTH AMERICA: OTHER IN VITRO TOXICOLOGY TESTING METHODS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 250
TABLE 317 EUROPE: OTHER IN VITRO TOXICOLOGY TESTING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 251
TABLE 318 ASIA PACIFIC: OTHER IN VITRO TOXICOLOGY TESTING METHODS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 251
TABLE 319 LATIN AMERICA: OTHER IN VITRO TOXICOLOGY TESTING METHODS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 252
TABLE 320 MIDDLE EAST: OTHER IN VITRO TOXICOLOGY TESTING METHODS MARKET,
BY REGION, 2024–2031 (USD MILLION) 252
TABLE 321 GCC COUNTRIES: OTHER METHODS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 252
TABLE 322 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY END USER,
2024–2031 (USD MILLION) 254
TABLE 323 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 255
TABLE 324 NORTH AMERICA: IN VITRO TOXICOLOGY TE